doi;PMID;section;ITC num;Ind studies num;questions;reviewer 1;reviewer 2;decision;identical;Notes reviewer 1;Notes reviewer 2
10.1080/10428194.2021.1913143;33896344;general_information;NA;NA;Medical Condition of Interest Name;NA;NA;relapsed and refractory multiple myeloma;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;general_information;NA;NA;Countries of first author affiliations;NA;NA;spain;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;general_information;NA;NA;Countries of last author affiliations;NA;NA;switzerland;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;general_information;NA;NA;Positions of study investigators (for any authors of the article, any that applies);NA;NA;Academic, Pharmaceutical Industry, Private Data Analysis Company;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;general_information;NA;NA;At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company;NA;NA;Yes;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;general_information;NA;NA;Mentioned sources of funding;NA;NA;Pharmaceutical Industry;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;general_information;NA;NA;Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article;NA;NA;Yes;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;general_information;NA;NA;Mention of a systematic review to find the studies to compare treatments of interest;NA;NA;Yes;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;1;Patient-level data used;NA;NA;Yes;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;1;Clinical Trial;NA;NA;Yes;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;1;NCT (only for clinical trial registered on clinicaltrials.gov);NA;NA;NCT03361748;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;1;Country where the clinical trial/observational study was conducted (international if more than one);NA;NA;international;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;1;Phase of the clinical trial (clinical trial only);NA;NA;2;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;1;Number of treatment arms (clinical trial only);NA;NA;1;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;2;Patient-level data used;NA;NA;No;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;2;Clinical Trial;NA;NA;Yes;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;2;NCT (only for clinical trial registered on clinicaltrials.gov);NA;NA;NCT02336815;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;2;Country where the clinical trial/observational study was conducted (international if more than one);NA;NA;international;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;2;Phase of the clinical trial (clinical trial only);NA;NA;2;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;2;Number of treatment arms (clinical trial only);NA;NA;1;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;3;Patient-level data used;NA;NA;No;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;3;Clinical Trial;NA;NA;Yes;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;3;NCT (only for clinical trial registered on clinicaltrials.gov);NA;NA;NCT03525678;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;3;Country where the clinical trial/observational study was conducted (international if more than one);NA;NA;international;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;3;Phase of the clinical trial (clinical trial only);NA;NA;2;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;study_information;NA;3;Number of treatment arms (clinical trial only);NA;NA;1;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Treatment name 1;NA;NA;idecabtagene vicleucel;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Study 'number(s)' for treatment 1;NA;NA;1;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Treatment name 2;NA;NA;selinexor + dexamethasone;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Study 'number(s)' for treatment 2;NA;NA;2;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Type of population-adjusted indirect comparisons performed;NA;NA;MAIC;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Anchored comparison?;NA;NA;No;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Form of the indirect comparison;NA;NA;Simple (ie treatments effects extracted from two studies);TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Definition of a single primary outcome for the indirect comparison;NA;NA;No primary outcome defined, or multiple primary outcomes without any clear distinction between them;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined);NA;NA;overall response rate;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Primary outcome: variable type;NA;NA;Binary (eg rates);TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Justification for selecting variables to be included in the adjustment model (in the main text);Nothing mentioned, not reported;Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose);Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose);FALSE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Inclusion of prognostic factors in the adjustment/matching model;NA;NA;Yes;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Inclusion of treatment-effect modifiers in the adjustment/matching model;NA;NA;No discussion (in the main text) of the status of treatment-effect modifiers of the variables;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc);NA;NA;No;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;1;NA;Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale);NA;NA;No;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Treatment name 1;idecabtagene vicleucel;idecabtagene + vicleucel;idecabtagene + vicleucel;FALSE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Study 'number(s)' for treatment 1;NA;NA;1;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Treatment name 2;NA;NA;belantamab mafodotin;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Study 'number(s)' for treatment 2;NA;NA;3;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Type of population-adjusted indirect comparisons performed;NA;NA;MAIC;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Anchored comparison?;NA;NA;No;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Form of the indirect comparison;NA;NA;Simple (ie treatments effects extracted from two studies);TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Definition of a single primary outcome for the indirect comparison;NA;NA;No primary outcome defined, or multiple primary outcomes without any clear distinction between them;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined);NA;NA;overall response rate;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Primary outcome: variable type;NA;NA;Binary (eg rates);TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Justification for selecting variables to be included in the adjustment model (in the main text);Nothing mentioned, not reported;Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose);Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose);FALSE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Inclusion of prognostic factors in the adjustment/matching model;NA;NA;Yes;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Inclusion of treatment-effect modifiers in the adjustment/matching model;NA;NA;No discussion (in the main text) of the status of treatment-effect modifiers of the variables;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc);NA;NA;No;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;methodology;2;NA;Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale);NA;NA;No;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;1;NA;Sample size of the population of interest in the non IPD treatment arm;NA;NA;122;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;1;NA;Initial sample size of the population of interest in the IPD treatment arm;NA;NA;128;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;1;NA;Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC;NA;NA;56;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;1;NA;Reporting of a weights' distribution evaluation (MAIC);NA;NA;Not mentioned;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;1;NA;Reporting of the list of the covariates adjusted for/matched on;NA;NA;Yes;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;1;NA;Number of covariates adjusted for/matched on;5;6;6;FALSE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;1;NA;Covariates adjusted for/matched on in the indirect comparison;NA;NA;Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;1;NA;Primary outcome: treatment effect contrast;NA;NA;OR;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;1;NA;Direction of the treatment effect contrast: IPD treatment is:;NA;NA;Numerator if ratio, or left side if difference;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;1;NA;Primary outcome: unadjusted treatment effect;NA;NA;7.78;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;1;NA;p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY]);NA;NA;"[4.43;13.65]";TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;1;NA;Primary outcome: adjusted treatment effect;NA;NA;7.74;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;1;NA;p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;NA;NA;"[3.83;15.62]";TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;2;NA;Sample size of the population of interest in the non IPD treatment arm;NA;NA;97;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;2;NA;Initial sample size of the population of interest in the IPD treatment arm;NA;NA;128;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;2;NA;Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC;NA;NA;45;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;2;NA;Reporting of a weights' distribution evaluation (MAIC);NA;NA;Not mentioned;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;2;NA;Reporting of the list of the covariates adjusted for/matched on;NA;NA;Yes;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;2;NA;Number of covariates adjusted for/matched on;NA;NA;6;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;2;NA;Covariates adjusted for/matched on in the indirect comparison;NA;NA;Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;2;NA;Primary outcome: treatment effect contrast;NA;NA;OR;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;2;NA;Direction of the treatment effect contrast: IPD treatment is:;NA;NA;Numerator if ratio, or left side if difference;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;2;NA;Primary outcome: unadjusted treatment effect;NA;NA;6.17;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;2;NA;p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY]);[3.15;NA;"[3.45;11.05]";FALSE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;2;NA;Primary outcome: adjusted treatment effect;NA;NA;5.12;TRUE;NA;NA
10.1080/10428194.2021.1913143;33896344;results;2;NA;p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;NA;NA;"[2.35;11.13]";TRUE;NA;NA
